MAP4K1 and neoplasm: The in vivo tumor growth inhibition observed in cancer models of various cellular origin (GL261 glioma, MC38 colon adenocarcinoma, and 1956 sarcoma) supports the broad potential application of a MAP4K1 inhibitor (12, 13).